Clinical Trial Search

Primary: Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo — -10.6; -10.4; -0.3 degree celcius — p=0.001

Primary: Percentage of Participants With Negative Ice Cube Provocation Test at Week 24 — 37.5; 40.5 percentage of participants — p=0.9492

Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…

Primary: Safety and Tolerability — 3; 7 Participants with a TEAE

Primary: Duration of Urticaria Until Remission Since Chronic Urticaria Was Diagnosed. — 18.5; 54; 67.7 percentage of participants

Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) Part A — 4; 0 Participants

Primary: Mean Pruritus Severity Score Over the First Week of Treatment — 1.02; 1.18 Units on a scale — p=<0.001

Primary: Time to 50% Decline in Clinical Symptoms Measured by the Urticaria Activity Score Seven Day(UAS7) — 23; 12 days

Primary: Reduction in Urticaria Activity Score (UAS7) — 3; 7 Participants

Primary: Proportion of Patients With Remission of Solar Urticaria Under Experimental Conditions (Phototesting) — 2 Participants

Primary: Area Under the Curve for Rewarming of Each Finger After Cold Challenge (AUC) as Measured by Thermography — 19558.43; 20045.96 C*sec — p==0.3801

Primary: The Change in Diary-based Clinical Symptoms as Measured by the Urticaria Activity Score 7 (UAS7) — 20.46; 24.59; 18.83; 18 UAS7 Scores

Primary: Change in Urticaria Activity Score 7 (UAS7) From Baseline to Week 4 — -6.91; -9.79; -19.93; -14.56 scores on a scale — p=0.1601

Primary: Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57 — -19.16; -24.05; -11.25; -15.69 Score on a Scale — p=0.0559

Primary: Change From Baseline in Post-provocation Urticaria Activity Score (UASprovo) — -1.1; -0.5 scores on a scale — p=0.277

Primary: Medication Usage — 2.8; 4.6; 2.0; 4.9 number of pills/day

Primary: Mean Change From Baseline in Blood Flow — 2558.65; 3470.13; 809.88; 960.86 Perfusion Units — p=0.3061

Primary: Total Symptom Score (TSS) Over Days 2 to 4 (TSS2-4) — 6.390; 5.777 units on a scale — p=0.0895

Primary: Change in the Basophil Proteome — 4; 0; 3 Participants

Primary: Mean Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint) — -19.41; -11.73 Unit on a scale — p=<…

Primary: Change in the Urticaria Activity Score (UAS) From Baseline to the Final Week for Desloratadine 5 mg Versus Desloratadine 20 mg — -1.0; -1.0; -1.1; 2.9 Units on a scale…

Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml

Primary: Change From Baseline to Week 12 in the Weekly Itch Severity Score — -3.63; -6.46; -6.66; -9.40 Units on a scale — p=0.0010

Primary: Number of Participants With Adverse Events — 3 participants

Primary: Change From Baseline in Weekly Urticaria Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint) — -20.02; -13.79 Scores on a scale — p=<0.001

Primary: Change From Baseline of Weekly Urticaria Activity Score (UAS7) at Week 24 — -20.36; -22.50; -21.26 Score on a scale

Primary: Change From Baseline of the Itch Severity Score (ISS7) Score After 12 Weeks of Treatment — -10.11; -9.66; -5.87 Score on a scale — p=<0.001

Primary: Percentage of Participants With Adverse Events — 78.3; 83.7 Percentage of participants

Primary: Number of Participants With Treatment Emergent Adverse Events — 62; 0; 3; 1 Participants

Primary: Net Proportional Change in Nasal Airway Resistance — 0.11; 0.04 proportional change (unit-less)